FDA-approved1,2Evidence: Large human trialsHormones · Cancer

Triptorelin1

Also called Trelstar1,2

Key takeaway

Triptorelin is a lab-made decapeptide (ten amino acids) that mimics gonadotropin-releasing hormone (GnRH), and is the active ingredient in Trelstar.1,2 FDA approved Trelstar in 2000 for advanced prostate cancer. With continued use it shuts down the pituitary signal that drives testosterone production.1,2 In the randomized trials described in its label, more than 90% of men reached castration levels of testosterone within about a month and stayed there through the study.1

Triptorelin at a glance

What it isA synthetic decapeptide agonist analogue of GnRH, the hypothalamic hormone that controls the pituitary’s reproductive hormones, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Trelstar with an original approval date of June 15, 2000, for advanced prostate cancer. The cited label has no boxed warning.1,2
Human evidenceTwo randomized, active-controlled trials and one single-arm trial in men with advanced prostate cancer, described in the label, measuring testosterone suppression.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is triptorelin?

Triptorelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide made in the hypothalamus.1

In the United States it is the active ingredient of Trelstar, approved under NDA 020715, according to Drugs@FDA.2

How does triptorelin work?

The label states that triptorelin was about 100 times more active than natural GnRH at releasing luteinizing hormone in laboratory studies of rat pituitary cells.1

Continued exposure desensitizes the pituitary, so testosterone falls to levels seen after surgical castration. The label notes that testosterone can briefly rise in the first weeks, which may temporarily worsen prostate cancer.1

What do human studies show?

In a randomized trial of 277 men with advanced prostate cancer, the label reports that 91.2% of evaluable men given Trelstar reached castration levels of testosterone by day 29, and 96.2% stayed at those levels from day 57 to day 253.1

In a randomized trial of 346 men comparing two Trelstar versions, 97.7% of evaluable men on the longer-acting version reached castration levels by day 29, according to the label.1

These trials measured testosterone, a hormone marker. The label’s clinical studies section does not report survival results for Trelstar.1

What the evidence base contains

  • Large randomized human trial A randomized, active-controlled trial in 346 participants, all men with advanced prostate cancer, comparing two Trelstar versions, described in the label as a basis of its effectiveness.1
  • Controlled human trial A randomized, active-controlled trial in 277 men with advanced prostate cancer comparing Trelstar with another approved GnRH agonist, described in the label.1
  • Small, short, or incompletely reported human study A single-arm trial in 120 men with advanced prostate cancer, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is triptorelin FDA-approved?

Yes. Drugs@FDA lists Trelstar, application NDA 020715, with an original approval date of June 15, 2000.2

The Trelstar label cited here (DailyMed SPL version 20, published July 10, 2026) states that it is indicated for the treatment of advanced prostate cancer.1

The label has no boxed warning. Its warnings cover allergic reactions, the early testosterone flare, metabolic changes such as high blood sugar, and an increased risk of heart attack, sudden cardiac death and stroke reported in men.1

Timeline

  1. FDA approves Trelstar, according to Drugs@FDA.2
  2. DailyMed publishes the Trelstar label version cited on this page.1

What is still unknown?

How testosterone suppression with triptorelin translates into survival compared with other treatments: the label’s trials measured hormone levels.1

Long-term effects of sustained low testosterone, which the label lists among its warnings, including effects on metabolism and the heart.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Triptorelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Triptorelin are a bounded selection, not every registration or paper about Triptorelin. For the years before Triptorelin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Triptorelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Triptorelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Trelstar for advanced prostate cancer. Randomized trials described in the label found that most men reached and kept castration levels of testosterone. The trials measured hormone suppression rather than survival.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Triptorelin?

FDA-approved as Trelstar for advanced prostate cancer. Randomized trials described in the label found that most men reached and kept castration levels of testosterone. The trials measured hormone suppression rather than survival.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
17
Drugs@FDA applications
4

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.↗Source date November 9, 2026
  2. Literature metadata · added November 15, 2026

    A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.↗Source date October 19, 2026
  3. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT07816562↗Source date September 11, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Triptorelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

67Selected dated records
69Connected citations
17Populated source years2000–2026
3/4Record lanes present

Registered human studies

Trial composition

27 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 3 11Not applicable 6Phase 2 6Phase 4 4Phase 1 1
Status at observationCompleted 25Recruiting 5

A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Clinical Trial 15Review 11Randomized Controlled Trial 8Multicenter Study 6Comparative Study 5Clinical Trial, Phase II 3Research Support, Non-U.S. Gov't 3Clinical Trial, Phase III 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
4
FDA Federal Register documents
3
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
67

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 67 dated records

Research hub

Explore the Triptorelin evidence record

Open all 67 records →
67Dated records
3Evidence types
67Cited public sources
17Source years

Change ledger

Recently changed for Triptorelin

Open all 67 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00003026

PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.

PeptideScanner change date
November 15, 2026
Cited source date
July 2, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00066690

PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.

PeptideScanner change date
November 15, 2026
Cited source date
August 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00066703

PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.

PeptideScanner change date
November 15, 2026
Cited source date
February 6, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Triptorelin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care.La Clinica terapeutica · 2025 Mar-Apr
  2. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.Expert review of clinical pharmacology · 2018 07 26
  3. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.Breast cancer (Dove Medical Press) · 2018 03 06
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07816562Registry update September 11, 2026 · current at observation
  2. NCT06513962Registry update August 31, 2026 · current at observation
  3. NCT00066690Registry update August 26, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA4

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. NDA208956Full FDA chronology · original submission status AP 2017-06-29
  2. NDA022437Full FDA chronology · original submission status AP 2010-03-10
  3. NDA021288Full FDA chronology · original submission status AP 2001-06-29
  4. NDA020715Full FDA chronology · original submission status AP 2000-06-15
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Triptorelin →

Evidence types

Coverage by source year

Selected records span June 15, 2000 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 67

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.↗

    PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.↗

    PubMed lists PMID 12092661 in International urology and nephrology as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07816562↗

    PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06513962↗

    PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00066690↗

    PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT05982093↗

    PeptideScanner retained ClinicalTrials.gov record NCT05982093 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-04-24, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05896566↗

    PeptideScanner retained ClinicalTrials.gov record NCT05896566 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT00066703↗

    PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.↗

  9. Literature metadata

    A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.↗

    PubMed lists PMID 10525370 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 1999-11 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.↗

    PubMed lists PMID 19888782 in Clinical drug investigation as Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.↗

    PubMed lists PMID 29177573 in Drugs as Journal Article, Review, with publication-date metadata of 2017-12 (month precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07128394↗

    PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026